Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 5.34 SEK 0.56% Market Closed
Market Cap: 1.4B SEK

Operating Margin
Oncopeptides AB

-393.8%
Current
-1 288%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-393.8%
=
Operating Profit
-246.5m
/
Revenue
62.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Oncopeptides AB
STO:ONCO
1.4B SEK
-394%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
392.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD
28%
AU
CSL Ltd
ASX:CSL
89.1B AUD
26%
NL
argenx SE
XBRU:ARGX
46B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.8B USD
8%
No Stocks Found

Oncopeptides AB
Glance View

Market Cap
1.4B SEK
Industry
Biotechnology

Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

ONCO Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-393.8%
=
Operating Profit
-246.5m
/
Revenue
62.6m
What is the Operating Margin of Oncopeptides AB?

Based on Oncopeptides AB's most recent financial statements, the company has Operating Margin of -393.8%.

Back to Top